ReviewFrontiers in physiology2026
Metabolic reprogramming in cardiac fibrosis: mechanisms, crosstalk, and therapeutic interventions.
Review in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac fibrosis is a pathological process accompanied by the development of cardiovascular diseases, which is mainly manifested as excessive deposition of extracellular matrix (ECM) of the heart muscle. Recent studies indicate that metabolic reprogramming significantly influences fibroblast activation, collagen deposition, and the fibrotic process by reshaping glycolytic, lipid, and amino acid metabolic pathways. This paper systematically reviews the mechanism of metabolic reprogramming in cardiac fibrosis and puts forward potential intervention strategies from a critical perspective. Although metabolic reprogramming shows potential in regulating cardiac fibrosis, its practical application still faces major challenges. Future research should strive to build a comprehensive research framework and promote metabolic reprogramming research to open a new way of precise intervention for the prevention and treatment of cardiac fibrosis through cross-technological innovation and precise regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.